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A series of asymmetrical 4-alkyl/aryl-2,6-dimethyl-3-N-(aryl/heteroaryl)-carbamoyl-5-ethoxycarbonyl-1, 
4-dihydropyridines 3a-d and symmetrical 4-alkyl/aryl-2,6-dimethyl-3,5-bis-(ethoxycarbonyl)-1,4-dihydropyridines 4a and 
4b have been prepared by the condensation of various benzaldehydes, ethylacetoacetate, 2-aminopyridine or p-toludine in 
ethanol (Hantzch method). The structures of all the synthesized 1,4-dihydropyridine derivatives have been confirmed by 
spectral data (IR, 1H NMR) and elemental analysis. Compounds 3a-c, 4a and 4b (10 mg/kg) have been evaluated for their 
anticonvulsant effect against pentylenetetrazole- induced convulsions with phenytoin (4 mg/kg) as the standard. The 
anticonvulsant potential of the newly synthesized compounds have been assessed on the basis of increase in latency (onset 
time) to induce convulsions; decrease in number of convulsions and increase in latency of death compared to control and 
standard. 
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Convulsion is where the body muscles contract and 
unwind quickly and over and again, bringing about a 
wild shaking of the body1. In 1950's Bromide was 
introduced as first true antiepileptic drug (AED). The 
usage of Bromide has decreased in twentieth century 
when Phenobarbitone was accidentally discovered to 
be effective in suppressing seizures. Due to the side 
effects, toxicity and teratogenic effects of current 
antiepileptic drugs in the treatment of epilepsy, calcium 
channel blockers as antiepileptic agents have recently 
been considered2. There are considerable evidences 
that calcium is an important factor for the induction of 
epilepsy. Specifically, interesting seizure-instigating 
administrators or frameworks cause a quick 
intraneuronal union of calcium particles3. In particular, 
unique seizure-inciting operators or systems cause a 
fast intraneuronal convergence of calcium particles, 
which is easily identified with the ensuing epileptiform 
movement4. Conversely, calcium channel inhibitors 
(1,4-dihydopyridines) are effective against the whole 
range of convulsive procedures including electro, 
pentylene tetrazole, sound and pressure-induced 
seizures. Nifedipine and other dihydropyridine 
derivatives such as nimodipine, nitradipine, and 
nisoldipine (Figure 1) are potent blockers of the 
calcium channels of smooth muscles and also bind with 
high affinity to the brain membranes, hence can be 
employed as antiepileptic agents5-8. Considering the 
anticonvulsant potential of 1,4-dihydropyridines and  
in continuation to our work9-14 on this scaffold herein 
we report the synthesis and anticonvulsant activity of 
4-alky/aryl-2,6-dimethyl-3-N-(aryl/heteroaryl)-carbomo 
yl-5-ethoxycarbonyl-1,4-dihydropyridines 3a-d and  
4-alkyl/aryl-2,6-dimethyl-3,5-bis-(ethoxycarbonyl)-1,4-
dihydropyridines 4a and 4b (Scheme I). 
 
Results and Discussion 
N-(aryl/heteroaryl)acetoacetamide 2 was synthesized 
from the reaction of p-toludine/2- aminopyridine and 
ethylacetoacetate 1 using conventional and microwave 
irradiation methods. In both the methods there was an 
increase in yield with increase in concentration of 
ethylacetoacetate up to 1:1.8 (p-toludine/ 
2-aminopyridine: ethylacetoacetate), beyond which it 
decreased. Hence this ratio where highest yield was 
 
Figure 1 — Potent calcium channel blockers 




obtained was chosen to synthesize the  
N-(aryl/heteroaryl) acetoacetamide needed for preparing 
1,4-DHPs 3a-d. Reaction of compound 2 with 
appropriate aromatic aldehydes in presence of 
ammonium acetate produced the unsymmetrical 
dihydropyridines 3a-d. Symmetrical 1,4-
dihydropyridines 4a and 4b were synthesized from the 
one-pot three component reaction of ethylacetoacetate, 
ammonium acetate and p-hydroxyphenyl or butyrl 







carboxylate, 3a: Brown solid. Yield 58%. m.p. 125-
130°C. IR: 3494 (N-H str), 2981 (C-H str), 1694 (-C=O 
str, Amide), 1579 (C=C str), 770 cm‾1 (C-Cl str); 
1H NMR (DMSO-d6): δ 1.09-1.13 (t, 3H, -CH2-CH3), 
2.11-2.25 (q, 2H, -CH3), 2.48 (s, 6H, 2× –CH3), 4.82 
(s, 1H, H4-DHP), 4.93 (s, 1H, NH-DHP), 7.11-8.34 (m, 
8H, Ar-H), 10.69 (s, 1H, CONH); 13C NMR (DMSO-
d6): δ 14.2, 18.8, 19.1, 43.5, 61.6, 103.5, 114.6, 118.2, 
126.2, 129.4, 133.6, 142.9, 150.5, 165.2, 167.2; LCMS: 
m/z 411.88 (M+), 413.13 (M + 2). Anal. Calcd for 
C22H22ClN3O3: C, 64.15; H, 5.38; N, 10.20. Found: C, 




late, 3b: Brown solid. Yield 60%. m.p. 120-123°C. IR: 
3370 (O-H str broad), 3295 (N-H str), 3105 (C-H str, 
aromatic), 2960 (C-H str, aliphatic), 1745 (C=O str, 
ester), 1660 (C=O str, amide), 1570 (C=C str) 1100 cm‾1 
 
 
Scheme I — Synthetic route for 1,4-dihydropyridine derivatives 
 




(C-O str); 1H NMR (DMSO-d6): δ 1.31 (t, 3H, -CH3), 
2.28 (s, 6H, 2× -CH3), 4.18 (q, 2H, -CH2), 4.78 (s, 2H, 
H4 + NH-DHP), 5.35 (s, 1H, -OH), 6.53-6.65 (m, 4H, 
Ar-H), 7.19-7.82 (m, 4H, Ar-H), 9.15 (s, 1H, CONH); 
13C NMR (DMSO-d6): δ 14.3, 18.7, 19.0, 43.5, 61.6, 
102.7, 114.2, 115.9, 118.2, 130.6, 137.0, 138.3, 149.5, 
150.1, 156.7, 163.1, 167.2; LCMS: m/z 393.44 (M+). 
Anal. Calcd for C22H23N3O4: C, 67.16; H, 5.89; N, 
10.68. Found: C, 67.18; H, 5.93; N, 10.65%. 
 
Ethyl-4-(3-chlorophenyl)-2,6-dimethyl-5-(p-tolylc 
arbamoyl)-1,4-dihydropyridine-3- carboxylate, 3c: 
Brown solid. Yield 58%, m.p. 128-133°C. IR: 3293  
(N-H str), 2984 (C-H str), 1635 (C=N str), 1750 (C=O, 
str, ester), 1590 (-C=O str, amide), 1561 (C=C str), 
1428 (C-H bend), 770 cm‾1 (C-Cl str); 1H NMR 
(DMSO-d6): δ 1.11 (t, 3H, -CH2-CH3), 2.22 (s, 6H, 2× 
-CH3), 2.48 (s, 3H, Ar-CH3), 3.34 (q, 2H, -CH2), 4.8  
(s, 1H, H4-DHP), 7.04-7.32 (m, 9H, Ar-H, NH-DHP), 
8.4 (s, 1H, CONH); 13C NMR (DMSO-d6): δ 14.5, 
18.6, 19.2, 21.4, 43.8, 61.7, 102.8, 121.6 125.8, 129.2, 
136.2, 138.3, 142.4, 149.8, 163.1, 167.4; LCMS: m/z 
424.92 (M+), 426.15 (M + 2). Anal. Calcd for 
C24H25ClN2O3: C, 67.84; H, 5.93; N, 6.59. Found: C, 




3d: Brown solid. Yield 50%, m.p. 126-129°C. IR: 
3315 (N-H str), 3115 (C-H str, aromatic), 2995 (C-H 
str, aliphatic), 1760 (C=O, str, ester), 1645 (C=O str, 
amide), 1585 (C=C str), 1076 (C-O bend), 785 cm‾1  
(C-Cl str); 1H NMR (DMSO-d6): δ 1.28 (t, 3H, -CH3), 
2.26 (s, 6H, 2× –CH3, DHP), 2.43 (s, 3H, -CH3), 4.23 (q, 
2H, -CH2), 4.78 (s, 1H, H4-DHP), 5.15 (s, 1H, NH-
DHP), 7.17-7.65 (m, 8H, Ar-H), 10.16 (s, 1H, CONH); 
13C NMR (DMSO-d6): δ 14.5, 18.6, 19.0, 21.3, 39.2, 
61.5, 102.5, 102.8, 121.5, 126.7, 128.7, 131.4, 137.8, 
143.4, 150.1, 163.1, 167.2; LCMS: m/z 424.92 (M+), 
426.15 (M + 2). Anal. Calcd for C24H25ClN2O3: C, 




ydropyridine-3,5-dicarboxylate, 4a: Brown solid. 
Yield 65%, m.p. 115-118°C. IR: 3365 (O-H str, broad), 
3010 (C-H str, aromatic), 2827 (C-H str, aliphatic), 1656 
(C=O, str), 1555 (C=C str), 1225 (C-N str), 1095 cm‾1 
(C-Ostr); 1H NMR (DMSO-d6): δ 1.31 (t, 6H, 2× -CH3), 
2.26 (s, 6H, 2× -CH3, DHP), 4.25 (q, 4H, 2× -CH3), 4.82 
(s, 2H, H4-DHP + NH-DHP), 5.38 (s, 1H, -OH),  
6.75-6.98 (m, 4H, Ar- H); 13C NMR (DMSO-d6): δ 
14.8, 19.5, 42.9, 62.5, 103.1, 116.4, 131.3, 137.0, 151.6, 
157.2, 168.9; LCMS: m/z 345.16 (M+). Anal. Calcd for 
C19H23NO5: C, 66.07; H, 6.71; N, 4.06. Found: C, 




3,5-dicarboxylate, 4b: Brown solid. Yield 48%, m.p. 
93-96°C. IR: 3254 (N-H str), 2917 (C-H str), 1646 (C=O 
str), 1525 (C=C str), 1210 (C-N str), 1080 cm‾1 (C-O 
str); 1H NMR (DMSO-d6): δ 0.92 (t, 6H, 3× -CH3), 1.10 
(q, 2H, –CH2), 1.32-1.35 (m, 10H, 2×- -CH3 + 2× -
CH2),2.26 (s, 6H, 2× -CH3, DHP), 3.51 (t, 1H, H4-
DHP), 4.12 (s, 1H, NH-DHP), 4.35 (q, 4H,2×- CH2-
CH3); 13C NMR (DMSO-d6): δ 14.5, 19.1, 23.8, 27.9, 
33.2, 34.5, 61.5, 109.3, 150.6, 167.8; LCMS: m/z 309.19 
(M+). Anal. Calcd for C17H27NO4: C, 65.99; H, 8.80; N, 
4.53. Found: C, 66.01; H, 8.78; N, 4.55%. 
 
 
Anticonvulsant effect of some synthesized 1,4-
dihydropyridine derivatives in mice using PTZ 
induced seizures 
 
The six test compounds (3a-d, 4a & 4b) were 
evaluated for anticonvulsant activity against PTZ 
induced seizures using Phenytoin as standard (Table I). 
All the tested compounds (3a-d, 4a and 4b) were found 
to possess anticonvulsant activity. The test compounds 
showed increase in latency to induce convulsions, 
Table I — Anticonvulsant effect of some synthesized  
1,4-dihydropyridine derivatives in rats using PTZ induced seizures 
Compd Dose (mg/kg) Latency to induce convulsions (min) No. of convulsions No. of Animals Died/used
Control(PTZ) 80 6.333 9 4/6 
Phenytoin 4 10± 1 3 2/6 
3a 10 8.33± 0.5 6 3/6 
3b 10 10± 0.9 5 5/6 
3c 10 11.83± 1.2 4 0/6 
3d 10 10± 1.2 5 0/6 
4a 10 10± 1 4 0/6 
4b 10 11.5± 1 3 0/6 




decline in number of convulsions and increase in 
latency of death compared to control and standard. 
Compounds 3c, 4b (10mg/kg body weight) were found 




Chemicals used in synthetic work were  
2-aminopyridine, p-toludine, ethylacetoacetate, and 
potassium-tert-butoxide, various benzaldehydes such 
as 2-chlorobenzaldehyde, 3-chlorobenzaldehyde,  
4-hydroxybenzaldehyde, butyraldehyde, and ethanol. 
Chemicals used for biological activity were phenytoin, 
pentylenetetrazole, DMSO. All the reactions were 
performed in dried borosil glass beakers, round bottom 
flasks, conical flasks. Domestic LG microwave oven 
was used for synthesizing compounds by microwave 
irradiation method. Precoated silica gel plates 
(MERCK) were used for TLC to monitor the progress 
of the reaction. Compounds melting points were 
determined by capillary method and are uncorrected. 
JASCO UV Chamber was used for detection of spots 
in TLC. IR Spectra were recorded on BRUKER FTIR 
Spectrophotometer. 1H NMR (300 MHz) and 
13C NMR (75 MHz) spectra were recorded on Bruker 
spectrometer using DMSO-d6 as solvent and TMS as 
internal standard. Mass spectra were obtained on 
Shimadzu LCMS 2010 spectrophotometer. Elemental 
analysis was performed on Perkin-Elmer 204B 
analyzer. 
 
General procedure for the synthesis of N-
(aryl/heteroaryl) acetoacetamide, 2 
 
(a) Conventional method 
A mixture of aryl/heteryl amine and 
ethylacetoacetate in 1:1.8 ratio and catalytic amount 
of potassium-tert-butoxide was taken into a 250 mL 
RB flask and dissolved in 25 mL of ethanol. The 
reaction mixture was heated under reflux for 6 to 
7hrs, while monitoring the progress of the reaction by 
TLC. The solvent was removed from the reaction 
mixture to a possible extent, under reduced pressure 
and the residue was cooled and triturated with dry 
ether. The product was filtered and washed with small 
portions of dry ether. Purification was effected by 
recrystallization from ethanol to obtain colorless 
crystalline solid13. 
 
(b) Microwave irradiation 
A mixture of aryl/heteryl amine, ethylacetoacetate 
in 1:1.8 ratio and a catalytic amount of potassium-
tert-butoxide was taken into a 250 mL Pyrex beaker 
with an inverted glass funnel and irradiated in a 
domestic microwave oven for 4 to 6 min with 10 sec 
pulses at 480W while monitoring the progress of the 
reaction by TLC. On completion of the reaction, the 
reaction mixture was cooled and triturated with ice-
cold ether. The product separated was filtered, washed 
with small portions of ice-cold ether and dried. 
Purification by recrystallization from ethanol afforded 
a colorless crystalline solid13. 
 
General procedure for the synthesis of 4-alky/aryl-
2,6-dimethyl-3-N-(aryl/heteroaryl)- carbomoyl-5-
ethoxycarbonyl-1,4-dihydropyridines, 3a-d 
A mixture of N-(aryl/heteroaryl)acetoacetamide  
(2 0.01mol), ethylacetoacetate (0.01mol), an 
appropriate aldehyde (0.01mol) and urea (0.01mol) in 
ethanol (25 mL) was heated under reflux, on a water-
bath for 15-25hrs while monitoring the reaction by 
TLC. On completion of the reaction, the solvent was 
removed to the possible extent by distillation under 
reduced pressure and the residue was cooled. The 
product was filtered, washed with small portions of 
ice-cold ethanol and dried. Further purification was 
effected by column chromatography by gradient 
elution technique14. 
 
General procedure for the synthesis of 4-
alkyl/aryl-2,6-dimethyl-3,5-bis- (ethoxycarbonyl)-
1,4-dihydropyridines 4a and 4b 
 
(a) Conventional method 
A mixture of ethylacetoacetate (0.02mol), an 
appropriate aldehyde (0.01mol) ammonium acetate 
(0.01mol) and catalytic amount of potassium-tert-
butoxide in ethanol (25 mL) was heated under reflux, 
on a water-bath for 6-7hrs while monitoring the 
reaction by TLC. On completion of the reaction, the 
solvent was removed to the possible extent by 
distillation under reduced pressure and the residue 
was cooled. The product was filtered, washed with 
small portions of ice-cold ethanol and dried. Further 
purification was effected by recrystallization from 
ethanol to obtain colorless crystalline solid14. 
 
(b) Microwave irradiation 
A mixture of ethylacetoacetate (0.02mol), an 
appropriate aldehyde (0.01mol) ammonium acetate 
(0.01mol) and catalytic amount of potassium-tert-
butoxide was taken into a 250 mL Pyrex beaker with 
an inverted glass funnel and irradiated in a domestic 
microwave oven for 4 to 6 min with 10 sec pulses at 




480 W while monitoring the progress of the reaction 
by TLC. On completion of the reaction, the reaction 
mixture was cooled and triturated with ice-cold ether. 
The product separated was filtered, washed with small 
portions of ice-cold ether and dried. Purification by 
recrystallization from ethanol afforded a colorless 
crystalline solid14. 
 
Evaluation of anticonvulsant activity 
 
PTZ induced Seizures 
Animals: Wister Albino rats of male sex, weighing 
150-200 gm were used. They were purchased from 
Mahaveer enterprises, Hyderabad and housed in 
different groups consisting of six animals in each 
group; in plastic cages under good hygienic 
conditions bedding of rice husk was replaced twice in 
a week so as to maintain good hygienic conditions. 
Ambient temperature of 25±1 ºC, relative humidity of 
45-55% and 12 hrs light: 12 hrs dark cycles were 
maintained in animal house. The animals had free 
access to water and standard pelleted diet, except 
during experimentation when food and water were 
withheld. All animals were routinely examined for 
infections, disorders and injuries and they were 
treated ethically and humanly. Thirty minutes before 
the experiment, animals were selected randomly and 
transferred into individual cages and allowed to 
acclimatize before injection of drugs or vehicle. The 
experimental protocol was approved by the Animal 
Ethical Committee (IAEC), Vaagdevi College of 
Pharmacy, Warangal (Application No: 2014/11/4/3). 
 
Preparation of doses: The drugs and chemicals 
were freshly prepared. Pentylenetetrazole (80 mg/kg, 
i.p.), a stock solution containing 8 mg/mL was 
prepared by dissolving it in distilled water. Phenytoin 
(4 mg/kg, i.p.), a stock solution containing 0.2 mg/mL 
was prepared by dissolving it in distilled water. The 
doses of test compounds were 10 mg/kg, i.p. and  
15 mg/kg, i.p. respectively and stock solutions of test 
compounds containing 1 mg/mL and 1.5 mg/ mL 
were prepared by dissolving the test compounds in 
dimethylsulphoxide. The injection volume was 
1mL/100 gm body weight of animal1. 
 
Procedure: The animals were first weighed and 
were selected for the experiment depending on 
weight. The animals were then divided into seven 
groups, of six animals each. One group was used for 
studying the effects of Pentylenetetrazole alone 
(Control) and the other for studying the protective 
effects of Phenytoin (Standard). The remaining five 
groups were used for studying the effects of 
synthesized compounds (Test). Pentylenetetrazole  
(80 mg/kg) was administered intraperitoneally to 
induce convulsions in control and the onset and 
severity of convulsions, and mortality was noted. PTZ 
was administered half an hour after administration of 
phenytoin or test compounds4. In phenytoin treated 
animals, either delay or complete abolition of 
convulsions was noted. The test group animals were 
observed for onset of convulsions and number of 
convulsions. The drug treated (standard/test) animals 
were observed following PTZ injection up to one 
hour. The anticonvulsant potential of newly 
synthesized compounds was evaluated on the basis of 
increase in latency (onset time) to induce convulsions; 
decrease in number of convulsions and increase in 
latency of death compared to control and standard1. 
 
Conclusion 
Compounds 3c, 4b (10mg/kg body weight) were 
found to be more potent than the standard, Phenytoin 
(4mg/kg body weight). Hence, in view of the 
anticonvulsant potency exhibited by the newly 
synthesized 1,4-dihydropyridine derivatives (3a-d, 
4a-b), there is a need to carry out further studies to 
explore their potential as novel anticonvulsants. 
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